The company will complete an expansion of its secondary packaging capabilities at its Ravensburg, Germany site by 2020.
On Oct. 24, 2018, Vetter, a provider of prefilled drug-delivery systems and packaging solutions, announced the expansion of its secondary packaging capabilities at its Ravensburg, Germany site.
The company reports that at the Ravensburg site, various syringes, cartridges, and vials, some with highly complex requirements, are currently packed on state-of-the-art lines. In addition to the existing area of approximately 6000 m2 (64584 ft2), an additional 2900 m2 (31215 ft2) will be available in a new building by 2020, enabling continued flexible planning of secondary packaging well into the future.
The expansion also includes investments in modern testing and analysis methods. In addition to standard release and stability tests (e.g., of syringes with a needle shield), the company will offer more extensive tests for autoinjectors starting in March 2019. This development was achieved through the efforts of a team of specialized engineers that worked on the development of a testing machine, enabling application simulations and digital documentation on auto-injectors, according to the company.
“Thanks to the modular use of manual, semi-automatic, and fully automatic machines, we are able to individually package anything from small clinical to large commercial quantities and, therefore, react flexibly to changing customer structures and requirements”, said Bernd Stauss, senior vice-president of Production and Engineering, Vetter, in a company press release.
Source: Vetter
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.